GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (NAS:URGN) » Definitions » ROC (Joel Greenblatt) %

UroGen Pharma (UroGen Pharma) ROC (Joel Greenblatt) % : -990.06% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is UroGen Pharma ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. UroGen Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -990.06%.

The historical rank and industry rank for UroGen Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:

URGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -8805.48   Med: -2580.85   Max: 159.6
Current: -967.99

During the past 9 years, UroGen Pharma's highest ROC (Joel Greenblatt) % was 159.60%. The lowest was -8805.48%. And the median was -2580.85%.

URGN's ROC (Joel Greenblatt) % is ranked worse than
66.14% of 1468 companies
in the Biotechnology industry
Industry Median: -338.875 vs URGN: -967.99

UroGen Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 30.50% per year.


UroGen Pharma ROC (Joel Greenblatt) % Historical Data

The historical data trend for UroGen Pharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UroGen Pharma ROC (Joel Greenblatt) % Chart

UroGen Pharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -3,868.48 -2,842.96 -2,139.91 -1,346.36 -1,377.19

UroGen Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,016.32 -1,191.04 -837.94 -659.36 -990.06

Competitive Comparison of UroGen Pharma's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, UroGen Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's ROC (Joel Greenblatt) % falls into.



UroGen Pharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.847 + 5.002 + 16.855) - (14.083 + 0 + 11.705)
=8.916

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.443 + 5.673 + 11.102) - (16.538 + 0 + 14.674)
=1.006

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of UroGen Pharma for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-74.304/( ( (2.728 + max(8.916, 0)) + (2.36 + max(1.006, 0)) )/ 2 )
=-74.304/( ( 11.644 + 3.366 )/ 2 )
=-74.304/7.505
=-990.06 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


UroGen Pharma  (NAS:URGN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


UroGen Pharma ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of UroGen Pharma's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


UroGen Pharma (UroGen Pharma) Business Description

Traded in Other Exchanges
Address
400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Executives
Jason Drew Smith officer: General Counsel C/O UROGEN PHARMA LTD., 400 ALEXANDER PARK DRIVE, PRINCETON NJ 08540
Robinson James A. Jr. director 852 WINTER STREET, WALTHAM MA 02451
Mark Schoenberg officer: Chief Medical Officer C/O UROGEN PHARMA LTD., 9 HA TA ASIYA STREET, RA ANANA L3 4365007
Daniel George Wildman director 12520 SUNNYDALE DRIVE, WELLINGTON FL 33414
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Dong Kim officer: Chief Financial Officer C/O UROGEN PHARMA, LTD., 400 ALEXANDER PARK DRIVE, 4TH FLOOR, PRINCETON NJ 08540
Elizabeth A. Barrett officer: Chief Executive Officer C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Molly Henderson officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Peter P. Pfreundschuh officer: CFO C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Stephen Mullennix officer: COO C/O UROGEN PHARMA LTD, 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Ran Nussbaum director C/O KITE PHARMA, INC., 2225 COLORADO AVENUE, SANTA MONICA CA 90404
Stuart Holden director C/O UROGEN PHARMA LTD., 9 HA'TA'ASIYA STREET, RA'ANANA L3 4365007
Cynthia M Butitta director 3165 PORTER DRIVE, PALO ALTO CA 94304
Ron Bentsur director, officer: Chief Executive Officer 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Fred E Cohen director 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102